Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Levosimendan: implications for clinicians.

Brian F McBride1, C Michael White

  • 1Hartford Hospital Drug Information Center, 80 Seymour Street, P.O. Box 5037, Hartford, CT 06102-5037, USA.

Journal of Clinical Pharmacology
|October 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nitrous oxide abuse prevalence, mechanisms, treatments and prevention.

Current medical research and opinion·2026
Same author

Identification and Characterization of Mitragynine or 7-Hydroxymitraynine Oral Dosage Form Products That Appeal to Children.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2026
Same author

Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown.

The Annals of pharmacotherapy·2026
Same author

Nonswallowed Kratom-Derived Products: Unlawful Dietary Supplements That Endanger Public Health.

Public health reports (Washington, D.C. : 1974)·2026
Same author

Transdermal "Natural GLP-1" Dietary Supplements Violate Law and Place Patients at Risk.

The Annals of pharmacotherapy·2026
Same author

Kratom's Use and Impact on Pediatric Populations.

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG·2025
Same journal

Population Pharmacokinetic Modeling and Simulation to Support the Regulatory Submission of the Two-Injection Start Regimen with Aripiprazole Once-Monthly Long-Acting Injectable Intramuscular Administration in Japanese Patients with Schizophrenia or Bipolar I Disorder.

Journal of clinical pharmacology·2026
Same journal

External Evaluation of Population Pharmacokinetic Models for Factor VIII in Chinese Patients with Hemophilia A.

Journal of clinical pharmacology·2026
Same journal

How to Replace the TQT Study-The Use of Concentration-QTc Modeling to Exclude a Small Effect of a Novel Drug on QT Interval: Historical Perspective and Implementation.

Journal of clinical pharmacology·2026
Same journal

Genome Sequencing Enhances Precision and Clinical Utility of Pharmacogenetic Data Compared to Arrays.

Journal of clinical pharmacology·2026
Same journal

FDA Gene Therapy Approvals (1998-2025): Current Status, Regulatory Evolution, and Future Directions.

Journal of clinical pharmacology·2026
Same journal

Human Disposition, Metabolism, and Excretion of Sevasemten (EDG-5506), a Selective Modulator of Fast Myosin in Healthy Volunteers.

Journal of clinical pharmacology·2026
See all related articles

Levosimendan, a novel heart failure drug, enhances heart muscle contraction without increasing calcium, reducing cell damage. It also widens blood vessels, improving outcomes and potentially lowering costs.

Area of Science:

  • Cardiology
  • Pharmacology
  • Heart Failure Management

Background:

  • Acute and chronic heart failure present significant therapeutic challenges.
  • Existing treatments have limitations in efficacy and safety.
  • Novel agents are needed to improve outcomes in heart failure patients.

Purpose of the Study:

  • To evaluate the novel calcium sensitizing agent, levosimendan, for heart failure treatment.
  • To assess levosimendan's mechanism of action, including myocardial force generation and vasodilation.
  • To examine the safety profile and potential benefits of levosimendan in heart failure.

Main Methods:

  • Levosimendan increases myocardial contractility via calcium sensitization.
  • It reduces myocyte calcium concentrations, mitigating the risk of myocardial necrosis.

Related Experiment Videos

  • The agent induces coronary and peripheral vasodilation, improving blood flow and reducing afterload.

    • Main Results:

    • Levosimendan demonstrated beneficial survival effects in various patient populations.
    • It improved patient outcomes compared to the standard of care.
    • The drug has the potential to reduce hospitalization costs associated with heart failure.

    Conclusions:

    • Levosimendan offers a promising therapeutic option for acute and chronic heart failure.
    • Its unique mechanism of action provides inotropic support with reduced risk of cellular damage.
    • Further evaluation is warranted regarding its long-term safety, particularly concerning arrhythmias and its use in specific patient groups.